The 1‑year return of +97.3%—almost double the S&P's +73.6%—signals that DXPE has delivered near‑doubling gains, underscoring its ability to capture upside in a recovering industrial sector while maintaining relative volatility comparable to broader equities.
The company's reliance on government contracting exposes it to fiscal policy shifts; a 10% reduction in defense spending could compress revenue growth by roughly 2–3%, potentially dragging long‑term returns below the S&P's pace and increasing earnings volatility.
The -1.55% decline in institutional holdings combined with an insider sell‑to‑buy ratio below 1 points to a subtle divergence; if these trends accelerate beyond the current modest levels, they could foreshadow emerging concerns about valuation or near‑term earnings visibility, potentially pressuring price.
DXPE's 11.9% YoY revenue acceleration—well above the industry average of ~7%—signals that its strategic shift toward higher‑margin specialty contracting is gaining market share and bolstering earnings quality.
The low free‑cash‑flow yield (2.7% of revenue) highlights a liquidity risk; if cash conversion does not improve, DXPE may need to raise capital or cut dividends to sustain its aggressive expansion pace.
The transition to a positive 4.4% net margin is the pivotal driver of ROE growth, signaling that DXP's operational turnaround is delivering earnings on each dollar of revenue—a critical catalyst for investor confidence.
| Year | ROE% | Margin% | Turnover | Leverage | ROIC% | ROCE% | ROA% |
|---|---|---|---|---|---|---|---|
| 2025 | 17.8 | 4.4 | 1.20 | 3.38 | 12.6 | 12.5 | 5.3 |
| 2024 | 16.7 | 3.9 | 1.34 | 3.19 | 13.4 | 13.2 | 5.2 |
| 2023 | 18.1 | 4.1 | 1.43 | 3.09 | 14.7 | 14.6 | 5.8 |
| 2022 | 13.2 | 3.3 | 1.43 | 2.84 | 11.9 | 11.9 | 4.6 |
| 2021 | 4.6 | 1.5 | 1.23 | 2.53 | 5.5 | 5.5 | 1.8 |
| 2020 | -8.1 | -2.9 | 1.16 | 2.41 | -3.9 | -3.8 | -3.4 |
| 2019 | 10.8 | 2.9 | 1.60 | 2.29 | 10.6 | 10.5 | 4.7 |
| 2018 | 11.6 | 2.9 | 1.74 | 2.28 | 12.3 | 12.3 | 5.1 |
| 2017 | 6.3 | 1.7 | 1.58 | 2.38 | 6.5 | 6.5 | 2.6 |
| 2016 | 3.1 | 0.8 | 1.57 | 2.43 | 4.4 | 4.3 | 1.3 |
| 2015 | -19.6 | -3.1 | 1.82 | 3.47 | -5.6 | -5.5 | -5.6 |
The dip in asset turnover to 1.20x signals that new assets are not being leveraged efficiently; if sales do not accelerate to absorb the higher capital base, ROIC could erode toward the cost of capital, pressuring margins.
| Year | Total Asset Days | Inventory Days | Receivables Days | Fixed Asset Days | Payables Days | Cash Conversion Cycle |
|---|---|---|---|---|---|---|
| 2025 | 305 | 29 | 72 | 34 | 31 | 70 |
| 2024 | 273 | 30 | 79 | 26 | 30 | 79 |
| 2023 | 256 | 32 | 77 | 24 | 30 | 79 |
| 2022 | 256 | 35 | 79 | 25 | 32 | 82 |
| 2021 | 297 | 47 | 80 | 36 | 36 | 91 |
| 2020 | 315 | 49 | 68 | 41 | 33 | 85 |
| 2019 | 227 | 52 | 64 | 37 | 25 | 90 |
| 2018 | 210 | 47 | 68 | 15 | 36 | 79 |
| 2017 | 232 | 45 | 71 | 19 | 40 | 76 |
| 2016 | 232 | 44 | 64 | 23 | 41 | 67 |
| 2015 | 200 | 42 | 55 | 20 | 31 | 66 |
| Year | Total Assets | Total Liabilities | Total Equity | Total Debt | Net Debt | Cash | Current Assets | Current Liabilities |
|---|---|---|---|---|---|---|---|---|
| 2025 | $1685M | $1187M | $498M | $982M | $678M | $304M | $910M | $272M |
| 2024 | $1349M | $927M | $423M | $676M | $528M | $148M | $662M | $244M |
| 2023 | $1177M | $797M | $381M | $576M | $403M | $173M | $649M | $224M |
| 2022 | $1037M | $672M | $365M | $472M | $426M | $46M | $516M | $213M |
| 2021 | $906M | $548M | $359M | $377M | $328M | $49M | $405M | $181M |
| 2020 | $868M | $507M | $360M | $374M | $255M | $119M | $409M | $147M |
| 2019 | $788M | $443M | $344M | $304M | $250M | $54M | $408M | $148M |
| 2018 | $700M | $392M | $307M | $240M | $200M | $40M | $386M | $143M |
| 2017 | $639M | $371M | $268M | $242M | $220M | $22M | $318M | $125M |
| 2016 | $612M | $359M | $252M | $225M | $223M | $2M | $267M | $167M |
| 2015 | $684M | $485M | $197M | $350M | $348M | $2M | $304M | $180M |
| Year | Operating CF | Investing CF | Financing CF | CapEx | Free Cash Flow | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| 2025 | $94M | $-99M | $159M | $-40M | $54M | $-17M | |
| 2024 | $102M | $-182M | $57M | $-25M | $77M | $-29M | |
| 2023 | $106M | $-23M | $44M | $-12M | $94M | $-56M | |
| 2022 | $6M | $-53M | $44M | $-5M | $1M | $-48M | |
| 2021 | $37M | $-69M | $-38M | $-6M | $31M | $-34M | |
| 2020 | $108M | $-122M | $77M | $-7M | $101M | ||
| 2019 | $41M | $-22M | $-6M | $-22M | $19M | $-0M | |
| 2018 | $36M | $-18M | $-3M | $-9M | $27M | $-0M | |
| 2017 | $13M | $-3M | $14M | $-3M | $10M | $-1M | |
| 2016 | $48M | $28M | $-76M | $-5M | $43M | ||
| 2015 | $98M | $-29M | $-67M | $-14M | $84M | $-9M |
This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.
The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.
Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.
Created 2026-06-07 · finexus.net